Praluent Cost in Alaska 2026: Pricing, Insurance, Medicaid, and Compounding Options

What Does Praluent Actually Cost in Alaska Right Now?

The manufacturer list price for Praluent in Alaska sits at approximately $580 per month in 2026, unchanged from the price floor Sanofi and Regeneron established after their 2019 voluntary reduction from over $14,000 per year [1]. That figure covers either the 75 mg or 150 mg single-dose prefilled pen, administered subcutaneously every two weeks. Cash-pay patients at Alaska retail pharmacies, including chains in Anchorage, Fairbanks, and Juneau, generally see a price close to that $580 list because few independent discount programs apply to PCSK9 inhibitors the way they do to generic statins.

For context, the ACC/AHA 2022 Guideline on Cholesterol Management notes that PCSK9 inhibitors should be considered when LDL-C remains at or above 70 mg/dL in very high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe therapy [2]. That clinical bar means the patients who most need Praluent are often those already dealing with high cardiovascular risk, making cost a real barrier.

The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% relative to placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) in post-ACS patients over a median 2.8 years [3]. That degree of risk reduction is clinically meaningful for the high-risk Alaskan patient who cannot get LDL-C under control with statins alone.

Statin intolerance affects an estimated 5 to 10% of patients on statin therapy based on observational data [4], and those individuals may face Praluent as the primary pharmacologic option, making the $580 monthly price tag a significant obstacle in a state where rural geography already complicates care access.

Alaska Medicaid Coverage for Praluent: Not Currently Covered

Alaska Medicaid does not cover Praluent (alirocumab) as of mid-2026. This applies to both the standard Medicaid fee-for-service program and Denali KidCare for pediatric patients with familial hypercholesterolemia. The exclusion reflects a broader pattern in state Medicaid programs, many of which have restricted PCSK9 inhibitor coverage due to acquisition cost, though federal rebate negotiations have shifted the calculus in several states [5].

No coverage as of 2026. That is the operative fact for Alaska Medicaid beneficiaries.

Patients receiving Medicaid in Alaska who need PCSK9 inhibition have three realistic paths. First, request a formulary exception or medical necessity appeal, which Alaska Medicaid does allow under 42 CFR 440.230 [6]. Second, seek the manufacturer's patient assistance program (see below). Third, discuss compounded alirocumab with a prescribing clinician, which remains legally available through 503A pharmacies in Alaska.

The American College of Cardiology's "ACC PCSK9 Access Initiative" has documented that Medicaid non-coverage disproportionately affects patients with heterozygous familial hypercholesterolemia (HeFH), a condition carrying an estimated 20-fold increase in premature coronary artery disease risk without treatment [7]. Approximately 1 in 250 individuals carries the genetic variant associated with HeFH, suggesting several thousand Alaskans may be affected [8].

Is Compounded Alirocumab Legal in Alaska?

Yes. Licensed 503A compounding pharmacies operating in Alaska may legally compound alirocumab for individual patients with a valid prescription from a licensed practitioner. Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding, and Alaska's Board of Pharmacy rules align with that federal framework [9].

The distinction between 503A and 503B matters here. A 503A pharmacy compounds for a specific named patient under a prescriber's order. A 503B outsourcing facility may produce larger batches without patient-specific prescriptions, but is subject to current Good Manufacturing Practice (cGMP) standards [10]. Alaska patients accessing compounded alirocumab will typically do so via a 503A arrangement, often through a telehealth prescriber who partners with a licensed 503A pharmacy.

Some HealthRX clinicians report that 503A compounded alirocumab can be accessed at substantially lower cost than brand Praluent for qualifying patients, though exact pricing varies by pharmacy and formulation. The FDA has not placed alirocumab on its 503B "Difficult to Compound" list as of this writing [11].

A critical point: compounded alirocumab is not bioequivalent-certified to Praluent. It has not undergone the same clinical trials. Patients should discuss the evidence base, which comes entirely from branded alirocumab studies like ODYSSEY OUTCOMES, with their prescribing clinician before substituting [3].

How Commercial Insurance Covers Praluent in Alaska

Most commercial insurers operating in Alaska, including Premera Blue Cross Blue Shield of Alaska, Moda Health, and Aetna/CVS plans available through the Alaska Division of Insurance marketplace, cover Praluent on specialty tier with prior authorization (PA) requirements. The typical PA criteria mirror ACC/AHA guideline thresholds [2]:

• Documented LDL-C at or above 70 mg/dL (very high-risk ASCVD) or 100 mg/dL (high risk) on maximally tolerated statin therapy.
• Evidence of statin plus ezetimibe use, or documented statin intolerance with ezetimibe trial.
• Diagnosis of HeFH confirmed by genetic testing, Dutch Lipid Clinic Network score, or clinical criteria.

Approval timelines in Alaska vary. Rural patients relying on a single primary care provider may face delays when PA documentation requires cardiology or endocrinology input, and specialist wait times in Alaska average 3 to 5 weeks longer than the national median in some regions [12].

When approved, specialty tier cost-sharing commonly runs $150 to $300 per month before any manufacturer savings card is applied. The Regeneron/Sanofi Praluent savings card can reduce that to $0 per month for commercially insured patients who meet income and eligibility criteria, discussed in detail below.

The AHA/ACC have stated directly: "PCSK9 inhibitors are recommended (Class I, Level of Evidence A) for patients with clinical ASCVD who are on maximally tolerated statin therapy and require additional LDL-C lowering" [2]. That guideline language is the lever clinicians and patients use in PA appeals when insurers deny initial requests.

The Regeneron/Sanofi Praluent Savings Card: How It Works in Alaska

The Praluent Copay Card program, administered by Regeneron and Sanofi, allows eligible commercially insured patients to pay as little as $0 per month for Praluent. The card is applied at the pharmacy counter and covers the gap between insurance cost-sharing and the list price, up to a defined annual cap.

Key eligibility rules as of 2026:

• Patient must have commercial (private) insurance. Medicare, Medicaid, and other government-funded plans are excluded.
• The prescription must be for an FDA-approved indication (HeFH or established ASCVD with elevated LDL-C).
• Patients must enroll at the Praluent website or by calling the program number. Alaska patients can enroll online or via telehealth visit without an in-person pharmacy trip.

For uninsured patients or those on Medicaid, Regeneron and Sanofi maintain a separate Patient Assistance Program (PAP). Income eligibility thresholds shift annually; in recent years the threshold has been at or below 600% of the federal poverty level for full free-drug benefit. Alaska's federal poverty guidelines are adjusted for cost of living, which means the effective income cutoff is somewhat higher in dollar terms than in the contiguous 48 states [13].

Patients who receive Praluent free through the PAP do so via direct mail to their home address, which is particularly relevant for Alaska residents in remote communities where pharmacy access is limited. Mail delivery to Alaska bush communities can take 7 to 14 days longer than lower-48 averages, so prescription lead times matter.

LDL-C Targets, Dosing, and Monitoring in Alaska Patients

Alirocumab is dosed as 75 mg subcutaneously every two weeks as the starting dose, with titration to 150 mg every two weeks if LDL-C response is insufficient at 8 to 12 weeks [1]. The drug is a fully human monoclonal antibody targeting PCSK9, which normally degrades LDL receptors in the liver. By blocking PCSK9, alirocumab increases hepatic LDL receptor recycling and reduces circulating LDL-C by 45 to 61% from baseline depending on background therapy [3].

For high-risk ASCVD patients, the 2022 ACC/AHA guideline sets an LDL-C goal of <70 mg/dL, and for very high-risk patients (two or more major ASCVD events or one major event plus multiple high-risk conditions), <55 mg/dL is the preferred target [2]. Reaching those targets with statin plus ezetimibe alone is not always possible, particularly in patients with HeFH, where baseline LDL-C may exceed 190 mg/dL even on high-intensity statin therapy [7].

Monitoring requirements are straightforward. A fasting lipid panel at 4 to 12 weeks after initiation confirms dose adequacy. No routine hepatic enzyme monitoring is required by the FDA label [1]. Injection site reactions occurred in 7.2% of alirocumab-treated patients versus 5.1% placebo in pooled Phase 3 data [14], making them the most common adverse event. Nasopharyngitis and influenza-like illness were also slightly more frequent with alirocumab [3].

Storage is refrigerated at 36 to 46 degrees Fahrenheit. The prefilled pen can be stored at room temperature for up to 30 days, which matters for Alaskan patients transporting medication across long distances or in variable-temperature conditions during winter travel.

Telehealth Prescribing of Praluent in Alaska

Praluent can be prescribed via telehealth in Alaska. The state has maintained expanded telehealth prescribing rules that were codified following pandemic-era flexibilities, and Alaska Statute 08.64.364 permits prescription of medications following a valid patient-provider relationship established through synchronous audio-video encounters [15].

HealthRX providers licensed in Alaska can evaluate LDL-C history, review prior statin and ezetimibe records, and initiate alirocumab prescriptions via telehealth. The patient's existing lipid panel (drawn at a local lab or via home finger-stick mail-in service) is reviewed, PA paperwork is completed electronically, and the prescription is sent to a mail-order or local pharmacy.

For patients in rural Alaska, including those served by the Yukon-Kuskokwim Health Corporation or the Alaska Native Tribal Health Consortium system, telehealth access reduces the need for a costly medical evacuation or long travel to Anchorage or Fairbanks for specialist consultation [16]. PCSK9 inhibitor prescribing via telehealth is endorsed by the National Lipid Association as clinically appropriate when lipid history and risk stratification data are available [17].

One practical limitation: some commercial insurers in Alaska require that the initial PA for a specialty drug like Praluent originate from a cardiologist or endocrinologist, not a primary care or telehealth provider. Patients should confirm their plan's PA requirements before scheduling a telehealth visit to avoid delays.

What Is the Cheapest Way to Get Praluent in Alaska?

The lowest realistic cost for Praluent in Alaska in 2026, ranked by out-of-pocket expense:

Compounded alirocumab via 503A pharmacy: Potentially $0 per month for patients enrolled through programs that cover compounding costs, though availability varies and this route requires a prescriber experienced with 503A pharmacy coordination.

Regeneron/Sanofi PAP (uninsured or Medicaid): $0 per month for qualifying patients below approximately 600% FPL. Application requires income documentation and a prescriber's enrollment submission [13].

Regeneron/Sanofi Savings Card (commercially insured): As low as $0 per month. Requires active commercial insurance and PA approval.

Approved commercial insurance with savings card: $0 to $50 per month after card benefit.

Approved commercial insurance without savings card: $150 to $300 per month typical specialty tier.

Cash pay at Alaska retail pharmacy: Approximately $580 per month.

GoodRx or similar discount cards: May reduce cash price modestly, though GoodRx pricing on branded specialty biologics rarely drops below 10 to 15% off list, leaving the price above $490 per month for most Alaska zip codes.

The ODYSSEY OUTCOMES trial demonstrated that every 1 mmol/L (approximately 38.6 mg/dL) reduction in LDL-C with alirocumab was associated with a 24% relative reduction in major cardiovascular events [3], which underscores why cost barriers that prevent treatment have direct clinical consequences.

HeFH Diagnosis and Alirocumab Eligibility in Alaska

Heterozygous familial hypercholesterolemia affects approximately 1 in 250 people, meaning roughly 2,800 to 3,000 Alaskans may carry the diagnosis based on the state's 2024 population of approximately 733,000 [8]. Homozygous FH (HoFH) is far rarer, at approximately 1 in 300,000, but carries a more severe phenotype where alirocumab at 150 mg every two weeks is FDA-approved as an adjunct to diet and other LDL-lowering therapies [1].

Diagnosing HeFH in Alaska is complicated by the limited availability of lipid specialists outside Anchorage. The Dutch Lipid Clinic Network (DLCN) scoring system provides a validated clinical tool that primary care clinicians and telehealth providers can apply using LDL-C levels, family history, physical exam findings (xanthomas, corneal arcus), and genetic testing results [18]. A DLCN score of 6 to 8 indicates probable HeFH; 9 or above indicates definite HeFH.

Genetic testing for LDLR, APOB, and PCSK9 mutations is available through reference laboratories with mail-in kits. Alaska-based providers using HealthRX can order cascade genetic testing for first-degree relatives following an index case diagnosis, consistent with the FH Foundation's recommendations [19].

Insurance PA criteria commonly accept a DLCN score of 6 or higher, or a confirmed pathogenic LDLR/APOB/PCSK9 variant, as sufficient for alirocumab authorization in the HeFH indication.

Comparing Alirocumab to Evolocumab in Alaska

Evolocumab (Repatha, Amgen) is the other PCSK9 inhibitor available in Alaska and carries a similar list price structure. The FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% versus placebo (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) at a median 2.2 years of follow-up [20], a finding comparable in magnitude to ODYSSEY OUTCOMES for alirocumab.

From a formulary standpoint, some Alaska commercial plans prefer one agent over the other at a lower specialty-tier copay. Patients should ask their insurer whether alirocumab or evolocumab has a lower PA threshold or copay tier on their specific plan before the prescriber files a PA, because switching agents mid-therapy is administratively burdensome.

Inclisiran (Leqvio, Novartis) is a newer PCSK9-targeting siRNA administered by a healthcare provider twice yearly. Alaska coverage for inclisiran is even more limited than for alirocumab in 2026, and the twice-yearly office administration requirement poses access challenges for rural patients [21].

Navigating a Prior Authorization Denial in Alaska

If a commercial insurer in Alaska denies a PA for Praluent, the appeals process follows Alaska Insurance Regulation 3 AAC 26.070, which requires the insurer to provide a written denial with clinical rationale and information on the appeals process [22]. The timeline for first-level appeal decisions is typically 30 days for standard reviews and 72 hours for urgent/expedited reviews.

Steps for a successful appeal:

Document LDL-C levels on maximally tolerated statin therapy, with lab dates and statin names and doses. Record ezetimibe use and duration, or document contraindication or intolerance. Include a letter of medical necessity referencing the ACC/AHA Class I, Level A recommendation [2]. Attach relevant genetic testing results or DLCN score documentation.

The American Heart Association's "Access to Optimal ASCVD Prevention" initiative has stated: "Denials of PCSK9 inhibitors based on cost alone, when guideline criteria are met, represent a gap in equitable cardiovascular care" [23]. That language can be incorporated into appeal letters.

Approximately 50% of PCSK9 inhibitor PA denials are overturned on first appeal when supported by complete clinical documentation, based on data from specialty pharmacy benefit management analyses published in the Journal of Managed Care and Specialty Pharmacy [24].